As of September 30th, we have officially closed the Paxlovid arm of the CanTreatCOVID study. We are pleased to announce that the data collected from our Paxlovid arm will be shared with the PANORAMIC trial, which shares the same eligibility criteria and framework as CanTreatCOVID. This will allow for a more comprehensive analysis of Paxlovid’s effectiveness across a broader population.

While the Paxlovid arm has concluded, our work continues. We remain committed to studying other potential treatments and are excited to announce that recruitment for our antioxidant therapy has begun!

COVID-19 treatments should be safe, easy to administer, accessible in the community and cause minimal side effects. Researchers considered antioxidant supplements in the earlier stages of the pandemic; however, decision-makers need more high-quality
evidence from clinical trials. Antioxidant therapy (300ug selenium, 40mg zinc, 45mg lycopene, and 1.5g Vitamin C) offers a promising solution, as it has the potential to provide similar results to current medications without the risk of side effects, and at a lower cost.

Adults aged 18 – 49 years with one or more chronic condition(s) or adults aged 50+ years who tested positive for COVID with symptoms starting within the last five days can participate.